Guest Blog: Is GRAIL the “holy grail” of cancer screening?
From Dr. Ronald Adler, why we should be wary of the promises of GRAIL and other liquid biopsy companies. More
From Dr. Ronald Adler, why we should be wary of the promises of GRAIL and other liquid biopsy companies. More
On the week of Dr. Bernard Lown's 99th birthday, we reflect on Dr. Lown's work connecting medical service to social activism, and understanding how this applies today. More
Racism must be destroyed for the health of us all, Dr. Vikas Saini writes, in response to recent police violence and protests. More
Clinicians may avoid deprescribing a blood pressure medication because they fear that patients' blood pressure will rise dangerously. For those clinicians, the new OPTIMISE trial results may put their mind at ease. More
Brooke McNaughton shares what she learned as a Lown public health intern during an unprecedented health crisis. More
Like so many other aspects of our health care system, the pandemic has laid bare the flaws in our electronic health record system. More
During this unprecedented health crisis, what will it take for hospitals to put aside their rivalries and work together? Shannon Brownlee and Vikas Saini discuss in the latest edition of "Lown Hospitals Q&A." More
Women make up 75-80% of health care workers, but only 13% of health care executives. In a new book, Dr. Patty Gabow explains why we should be encouraging more female leadership in health care and provides a guide for aspiring health care leaders. More
What can hospitals do to address health disparities in their communities? Vikas Saini and Shannon Brownlee answer questions about health disparities in this edition of our new video series, "Lown Hospitals Q&A." More
In recent years, extreme disparities in maternal mortality in the US have been brought to light. Could new hospital policies in the pandemic make these disparities worse? More
Lown's newest public health intern Bruce Jobse shares a story about how even when clinicians and patients believe they are doing “everything right,” misunderstandings and lack of trust can still make things go wrong. More
Since the release of the initial NIH study results, clinicians and researchers have posed many questions about remdesivir, which have so far gone unanswered. Here are a few of them... More
A study found that preventive cancer screenings sharply declined due to Covid-19. What effect will this dramatic decline in screening have on patient health? More
The pharmaceutical industry often justifies high drug prices by claiming that they create more innovation, but two recent studies find that drug costs and clinical benefit are often not related. More
Some states are ramping up their contact tracing capacity-- but are they hiring enough tracers to open up safely? More
There have been many instances of nurses being exploited, abandoned, and silenced in this pandemic. They deserve better. More
How is the FDA measuring success when it comes to approval for new cancer drugs? More
In "Issues in Science and Technology," Shannon Brownlee and Jeanne Lenzer explain how our toxic legacy of bad science in medicine has affected coronavirus research. More
What are elective surgeries and why are they so important to hospitals? Vikas Saini and Shannon Brownlee answer questions about elective surgeries in this edition of our new video series, "Lown Hospitals Q&A." More
Breaking down the flawed logic of "What do we have to lose?" when it comes to untested Covid-19 treatments. More